U.S., Dec. 24 -- ClinicalTrials.gov registry received information related to the study (NCT07299825) titled 'A Study of A166 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer' on Dec. 03.
Brief Summary: Evaluation of the efficacy of A166 in Patients with HER2-Positive unresectable or metastatic breast cancer previously treated with TOP1 inhibitor Antibody-Drug Conjugates
Study Start Date: Sept. 20, 2024
Study Type: INTERVENTIONAL
Condition:
Her 2 Positive Breast Cancer
Intervention:
DRUG: A166
intravenous(IV) infusion (Q3W)
Recruitment Status: RECRUITING
Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Disclaimer: Curated by HT Syndication....